Eton Pharmaceuticals Inc

ETON

Latest QuantConomy context for ETON: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class

stock

Primary venue

NASDAQ

Recent signals

SEC filings

Asset profile

QuantConomy has a structured record for ETON. More descriptive asset metadata will appear here when the platform record includes it.

Latest signal rows

Recent signals for ETON

Scored rows are pulled from the same signal API used by the digests.

Signal	Direction	Score	Observed	Reason
insider trade large sale	slightly bearish	30	Jul 7, 10:31 PM	Opaleye Management Inc. sold ETON shares ($2.43M) - 65,000 shares - [very weak slightly bearish signal]
fundamental gross profit change	very bearish	76	May 14, 12:00 AM	ETON (Q1 2026, gross profit): declined 65.5% ($42.74M → $14.73M). [sequential period basis, very bearish signal]
fundamental net income change	very bullish	68	May 14, 12:00 AM	ETON (Q1 2026, net income): turned profitable (-$4.60M → $1.55M). [sequential period basis, very bullish signal]

FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.

Market	Exchange	Source	Asset record
ETON	NASDAQ	fmp	Eton Pharmaceuticals, Inc.
ETON	NASDAQ	alpaca	Eton Pharmaceuticals, Inc. Common Stock
ETON	NASDAQ	alphavantage	Eton Pharmaceuticals Inc

Buys, last 90d

Sells, last 90d

Rows

Date	Insider	Role	Type	Shares	Price	Value	Filing
Jul 2, 2026	Opaleye Management Inc.	Insider	sale	65,000	$37.39	$2,430,032	4 on EDGAR
Jun 17, 2026	Adams Jennifer McKie	Insider	exercise	50,000	$3.78	$189,000	4 on EDGAR
May 28, 2026	BRYNJELSEN SEAN	President & CEO	sale	119,852	$31.88	$3,820,882	4 on EDGAR
May 22, 2026	Krempa David	Chief Business Officer	exercise	30,591	$3.58	$109,516	4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.